
CJC-1295 + Ipamorelin — pulsatile GH-axis support.
A protocol built around CJC-1295 and Ipamorelin — a GHRH analog paired with a selective GH secretagogue. CJC-1295 raises the baseline of growth-hormone release while Ipamorelin adds clean, selective pulses without elevating cortisol or prolactin. Together they restore a natural, pulsatile GH rhythm to support energy, body composition, and sleep.
Who it's for: Adults in their 30s, 40s, and 50s noticing energy, body-composition, or recovery declines associated with age-related GH decline.
ENERGIZER pairs 2 compounds:
CJC-1295 (GHRH analog)
GHRH analog that stimulates the pituitary to release growth hormone, raising both the amplitude and frequency of natural GH pulses. Provides the steady baseline of the GH-axis pair.
Used for
Ipamorelin (selective GH secretagogue)
Selective ghrelin-receptor agonist that produces a clean GH pulse without elevating cortisol, prolactin, or ACTH. Adds the sharp pulse that pairs synergistically with CJC-1295.
Used for
The following reflects areas of interest commonly reported by members and studied in the clinical literature. Results depend on individual health status, labs, and physician-directed care. Nothing below constitutes a treatment claim.
GH is central to cellular energy metabolism. The pair supports natural pulsatile GH secretion — relevant for adults whose endogenous GH has declined with age.
GH influences lean mass and fat metabolism. Paired with training and labs-monitored hormone status, ENERGIZER addresses the hormonal context body composition operates in.
Most natural GH secretion occurs during slow-wave sleep. Dosed at bedtime, the pair aligns with the nocturnal GH pulse — members commonly report deeper sleep and faster recovery within weeks.
ENERGIZER is prescribed and monitored against labs. The Halftime Baseline panel ($249, separate onboarding deliverable) covers the relevant markers below.
ENERGIZER is most commonly chosen by members whose primary intent is one of:
Available at every tier
The Halftime Baseline lab panel ($249) is a separate onboarding deliverable, available at any tier.
Join the waitlistLaunching July 1, 2026
All prescriptions require physician evaluation. Compounded medications are not FDA-approved. Individual results vary. This is not medical advice.